China Resources Sanjiu Medical & Pharmaceutical Co.Ltd(000999) independent director
Independent opinions on relevant deliberations of the second meeting of the board of directors in 2022
1、 Independent opinions on the departure of the president of the company
In accordance with the guiding opinions on the establishment of independent director system in listed companies, the Listing Rules of Shenzhen Stock Exchange and other laws and regulations and the articles of association, we, as independent directors of China Resources Sanjiu Medical & Pharmaceutical Co.Ltd(000999) (hereinafter referred to as “the company”), have verified Mr. Qiu Huawei’s departure from the post of president of the company. We hereby express our opinions on the verification as follows:
1. In order to implement the three-year action plan for the reform of state-owned enterprises and strengthen the construction of the board of directors and management team, Mr. Qiu Huawei, chairman of the company, nominated Mr. Zhao Bingxiang as president of the company. Mr. Qiu Huawei no longer serves as the president of the company and continues to serve as the chairman of the company. The reason for his departure is consistent with the actual situation.
2. Mr. Qiu Huawei’s departure as president of the company shall take effect upon deliberation and approval by the board of directors of the company. Mr. Qiu Huawei continues to serve as the chairman of the company.
3. The departure of the president will not have a significant impact on the company’s daily operation and management.
2、 Independent opinions on the appointment of senior managers of the company
China Resources Sanjiu Medical & Pharmaceutical Co.Ltd(000999) (hereinafter referred to as “the company”) the second meeting of the board of directors in 2022 was held on January 13, 2022. The meeting deliberated on the proposal on the change of the president of the company and the proposal on the appointment of senior managers of the company. In accordance with the guiding opinions on the establishment of independent director system in listed companies, the guidelines for the governance of listed companies, the Listing Rules of Shenzhen Stock Exchange and other laws and regulations and the articles of association, as independent directors of the company, after fully understanding the relevant conditions, we express our opinions as follows:
(I) legal procedure. The board of directors has considered and agreed to appoint Mr. Zhao Bingxiang as the president and Mr. Wu Wenduo as the vice president of the company, and the appointment procedure is legal; The deliberation and voting procedures of the board of directors on this matter are legal.
(II) legal qualification. After reviewing the personal resumes of Mr. Zhao Bingxiang and Mr. Wu Wenduo, it is not found that they are not allowed to serve as senior managers of the company as stipulated in the company law, have not been punished by the CSRC and other relevant departments and the stock exchange, and are not the person subject to dishonesty. After investigation, Mr. Zhao Bingxiang and Mr. Wu Wenduo have the qualifications of senior managers of the company, and have the professional quality, professional knowledge and work experience required to serve as senior managers of the company.
In conclusion, we agree with the voting results of the above proposals at the second meeting of the board of directors in 2022.
It is hereby announced.
Independent directors: Yao Xingtian, Tu Pengfei, Xu Fang, Liu Junyong January 13, 2002
